13 Best Growth Stocks to Buy Right Now
On March 16, Chief Investment Strategist at Hightower Stephanie Link and Chief Investment Officer at NFJ Investment Group John Mowrey joined CNBC to discuss oil shocks and market opportunities.
Arcutis Biotherapeutics Inc. (ARQT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Suvretta Capital Management Aaron Cowen | 11,964,000 | $347,434,560 | +15% | 7.12% |
| 2. | Rubric Capital Management David Rosen | 8,271,577 | $240,206,596 | -24% | 2.87% |
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 5,556,169 | $161,351,148 | +5% | 0.62% |
| 4. | D E Shaw D. E. Shaw | 2,683,087 | $77,916,846 | +27% | 0.04% |
| 5. | Driehaus Capital Richard Driehaus | 2,562,445 | $74,413,403 | +134% | 0.51% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.08 | 2,646 | $34,610.47 | 27,448 | 2025-06-13 | Filing | |
| $13.41 | 378 | $5,069.28 | 24,802 | 2025-06-05 | Filing | |
| $13.32 | 1,890 | $25,177.45 | 24,424 | 2025-06-04 | Filing | |
| $13.65 | 2,520 | $34,398.00 | 22,534 | 2025-05-22 | Filing | |
| $13.66 | 2,520 | $34,423.20 | 20,014 | 2025-05-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.39 | 39,272 | $997,194.62 | 22,123 | 2026-03-02 | Filing | |
| $25.65 | 10,000 | $256,518.00 | 49,744 | 2026-03-02 | Filing | |
| $25.91 | 103 | $2,669.23 | 175,178 | 2026-03-02 | Filing | |
| $25.16 | 3,584 | $90,177.02 | 175,281 | 2026-03-02 | Filing | |
| $25.91 | 1,068 | $27,676.05 | 785,957 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,874,511 | $286,755,799 | 7.7% | |
| 2. | 9,099,579 | $264,251,774 | 0% | |
| 3. | 7,253,936 | $210,654,301 | 0% | |
| 4. | 6,758,006 | $196,252,495 | 0.12% | |
| 5. | 5,488,301 | $159,380,261 | 0.01% |
News See All
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating
On February 27, 2026, Guggenheim raised its price target on Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) to $35 from $34 and maintained a Buy rating.
10 Fastest Growing NASDAQ Stocks to Buy
High growth stocks have once again taken center stage, and major asset managers argue that earnings momentum remains the decisive factor. In its 2026 Year-Ahead Investment Outlook, J.P.
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Arcutis Biotherapeutics, Inc. Fourth Quarter Fiscal Year 2025 Earnings Conference Call.
Baron Health Care Fund is Expecting High Operating Margins for Arcutis Biotherapeutics (ARQT)
Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here.
Arcutis (ARQT) Soars to Record High on Swing to Profitability, 'More-Than-Double' Revenues
Arcutis jumped to a fresh record high on Tuesday, as investors cheered a stellar earnings performance in the third quarter of the year, having more than doubled its revenues to reach profitability during...
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2025 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2025 Earnings Call Transcript October 28, 2025Arcutis Biotherapeutics, Inc. beats earnings expectations.
Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream
Arcutis Biotherapeutics, Inc.
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA For ZORYVE
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 14 Best Small Cap Stocks to Buy Right Now. On September 3, Arcutis Biotherapeutics, Inc.
Hedge Fund Resource Center